Fibroblast growth factor receptor 1/Klothoβ agonist BFKB8488A improves lipids and liver health markers in patients with diabetes or NAFLD: A phase 1b randomized trial.

Chin WongAjit DashJill FredricksonNicholas Lewin-KohShan ChenKenta YoshidaYanqiu LiuJohnny GutierrezRebecca Kunder

Published in: Hepatology (Baltimore, Md.) (2022)

BFKB8488A was adequately tolerated in patients with T2DM or NAFLD, leading to triglyceride reduction, HDL improvements, and trends in improvement in markers of liver health for both populations and marked liver fat reduction in patients with NAFLD. (ClinicalTrials.gov: NCT03060538).

Keyphrases

healthcare
public health
mental health
health information
metabolic syndrome
type diabetes
human health
risk assessment
binding protein
social media